University Hospitals Case Medical Center was recognized today as a national model for quality care as the recipient of the 2012 American Hospital Association-McKesson Quest for Quality Prize. The prestigious award named UH Case Medical Center the top hospital in the nation for its leadership and innovation in quality improvement and safety.
UH Case Medical Center was selected by a multi-disciplinary committee of health care quality and patient safety experts. The American Hospital Association (AHA)-McKesson Quest for Quality Prize is presented annually and UH Case Medical Center is the first large, urban academic medical center to earn this coveted prize.
To view Multimedia News Release, go to https://www.multivu.com/mnr/57289-american-hospital-association-uh-case-medical-center-leader-in-quality
Aflac, the number one provider of supplemental insurance in the United States, and recognized six times by Ethisphere as one of the World’s Most Ethical Companies, is once again teaming with Macy’s to produce and sell the 2012 Aflac Holiday duck . This is the twelfth year that Aflac and Macy’s are selling the annual plush duck, with all net proceeds going to support research and treatment for childhood cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58454-aflac-macys-annual-holiday-duck-design-pediatric-cancer-patient-atlanta
Ahead of World Stroke Day 2012 (October 29), European Policy Makers have joined over 90 Medical and Patient Organisations, and more than 100,000 people, in supporting the Global Atrial Fibrillation (AF) Patient Charter and calling for National Governments and the World Health Organisation to act to make the prevention of AF-related strokes a priority. The Charter outlines ways to improve the diagnosis and management of AF which, if implemented, could stop thousands of preventable strokes from occurring each and every year.
To view Multimedia News Release, go to http://www.multivu.com/players/English/57497-sign-against-stroke/
Global health service company Cigna is on a mission: to get HopeLab’s cancer-fighting game app Re-Mission 2: Nanobot’s Revenge onto the phones and tablets of every young cancer patient in the world. The free app is available for Android and iOS (Apple) mobile devices.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/62267-cigna-hopelab-re-mission-2-mobile-app
Crosstex International, a subsidiary of Cantel Medical Corp. (NYSE:CMN), and Prestige Ameritech, the only two major U.S.-based medical mask manufacturers have joined forces to bring attention to a glaring void in public health research and policy – that, if addressed, has the potential to more quickly provide a simple, effective tool to mitigate the spread of influenza and other respiratory borne viruses. The awareness campaign comes in response to a new study, “ Exposure to Influenza Virus Aerosols During Routine Patient Care,” published in The Journal of Infectious Diseases, showing that influenza viruses may spread as far as six feet from a person coughing or sneezing, and that some people, referred to as “super spreaders,” may be more likely to spread the virus. The study, supported by the Department of Health and Human Services with a $600,000 research grant, pointed specifically to concerns for healthcare workers being exposed to coughs from sick patients. Yet government research and policy continues to overlook face masks as a feasible protection measure for both the healthcare industry and the general public.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60417-cantel-medical-fitted-mask-infectious-disease-control-public-health-policy
The number of gout patients is rising, with an estimated 8.3 million American adults diagnosed with gout—but only 10 percent of them are being properly treated, according to the Gout & Uric Acid Education Society. To heighten awareness and knowledge about gout and to lead to earlier diagnosis and treatment, the society has released two new comprehensive kits to educate patients and provide consistent information for medical professionals. The release of the Take a Stand on Gout Patient Education Kit and Medical Professional Information Kit coincides with Gout Awareness Day, an annual commemoration on May 22 to call attention to the growing incidence of gout and to enhance knowledge so as to improve patient outcomes. Both kits provide new, substantial information about gout from specialists, who treat gout patients every day.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61805-gout-uric-acid-education-society-take-a-stand-on-gout-new-information-kits
The Gout & Uric Acid Education Society (GUAES) has added six new educational videos for patients and medical professionals to its library of popular educational videos on gout, highlighting the society’s most important takeaways from the recently released American College of Rheumatology (ACR) Guidelines on Gout Diagnosis and Treatment. Available under the patient and medical professional portals on www.GoutEducation.org, respectively, the latest videos emphasize the need for continuous communication between gout patients and their doctors about their unique treatment plan, to help prevent gout flares and long-term complications from this poorly understood form of inflammatory arthritis.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60699-gout-uric-acid-education-society-guaes-new-videos-on-acr-guidelines
The Preeclampsia Foundation today released the Illustrated Preeclampsia Symptoms Tear Pad, a patient education tool that was developed in collaboration with health services researchers at Northwestern University Feinberg School of Medicine in Chicago, Ill. The tool effectively informs pregnant women, even those with potentially poor literacy, about preeclampsia. Because preeclampsia is a disorder that can have grave consequences for a mother and her unborn baby, the goal is for the tool to offer information in a way that allows women to assimilate and retain knowledge related to preeclampsia, leading them to promptly seek medical attention should they have symptoms related to preeclampsia.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61626-preeclampsia-foundation-illustrated-symptoms-tear-pad-for-pregnant-women
Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced that its epilepsy-focused educational website, Epilog.us [http://www.Epilog.us], now features a panel discussion of leading experts on the role of rational polytherapy in the treatment of patients with epilepsy, led by Dr. Barry Gidal, Professor of Pharmacy and Neurology/Division Chair, University of Wisconsin. Dr. Gidal also brings forward discussion on the mechanism of action of specific antiepileptic drugs (AEDs). Additional topics include: AED pharmacokinetics; patient adherence and AEDs; and drug interactions.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59891-upsher-smith-epilog-us-pharmacodynamics-of-antiepileptic-drugs-aeds
Diabetes experts met and determined that some self-monitoring blood glucose (SMBG) systems, despite meeting accuracy standards at the time of U.S. Food and Drug Administration (FDA) clearance, fail to consistently meet accuracy standards once on the market, potentially putting patient health at risk. In a public meeting convened by the Diabetes Technology Society on May 21, 2013, in Arlington, Virginia, leading academic clinicians, clinical chemists, medical device experts, patient advocates and FDA representatives reviewed a growing body of peer-reviewed research demonstrating that the performance of some blood glucose monitors on the market may not be meeting accuracy standards.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/61870-diabetes-technology-society-inaccurate-blood-glucose-monitors-risky
Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient’s immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children’s Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64394-chop-penn-harness-engineered-t-cells-eliminate-tumors-in-blood-leukemia
